Premium
Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
Author(s) -
Atamaniuk Johanna,
Gleiss Andreas,
Porpaczy Edit,
Kainz Birgit,
Grunt Thomas W.,
Raderer Markus,
Hilgarth Bernadette,
Drach Johannes,
Ludwig Heinz,
Gisslinger Heinz,
Jaeger Ulrich,
Gaiger Alexander
Publication year - 2012
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.2012.02679.x
Subject(s) - multiple myeloma , bone marrow , medicine , myeloma protein , cancer research , receptor , oncology
Eur J Clin Invest 2012; 42 (9): 953–960 Abstract Background G protein‐coupled receptor 5D (GPRC5D) is a novel surface receptor. As this new subtype of G protein‐coupled receptors was discovered, little is known about the role of this gene. Materials and methods In this retrospective study, we investigated GPRC5D mRNA expression by real‐time polymerase chain reaction (RT‐PCR) in bone marrow (BM) of 48 patients with multiple myeloma (MM). Results Highly variable levels of GPRC5D (median, 288; quartiles, 17–928) were detected in patients with MM, whereas only low expression was detected in normal tissues (median, 1; quartiles, 1–23). High mRNA expression of GPRC5D correlated positively with high plasma cell count in bone marrow ( r = 0·64, P < 0·001), high β 2 ‐microglobulin ( r = 0·42, P = 0·003) and poor‐risk cytogenetics: deletion 13q14 (rb‐1), P = 0·003; and 14q32 translocation t(4;14)(p16;q32), P = 0·029. GPRC5D mRNA expression showed a significant correlation with overall survival ( P = 0·031). The estimated overall survival of patients expressing GPRC5D above or below the median of 288 was 43·9% vs. 70·2% at 48 months. Here, we report, for the first time, the association of GPRC5D expression and cancer. Conclusions Overexpression in poor‐risk myeloma, low expression in normal tissues and cell surface expression identify GPRC5D as a potential novel cancer antigen. Our data demonstrate that GPRC5D is a prognostic factor in MM correlating with other major risk factors.